The new reality of investing (2024 edition)

Biotech investing often hinges on understanding science, trials and patient outcomes. Dr. Judith Finegold is a physician turned equity analyst, and she explains how her clinical experience helps assess drug pipelines, clinical trials and long term risk in biotech investing — well ...  Show more

Capital Group equity portfolio manager Chris Buchbinder and economist Jared Franz stress test the bull and bear cases for AI. They cover whether we are in an AI boom or bubble and what productivity gains could mean for the U.S. economy and job markets. This podcast is from a rece ...  Show more

Welcome back to the Wise Investor Segment, where we delve deep into the world of real estate investment to uncover the latest trends and challenges facing investors.

In this episode, we explore the dynamic landscape of real estate investing in the current year. From shi ...

The 28th annual edition of our 2024 Long-Term Capital Market Assumptions explores how investors can build on the 60/40 portfolio – using new axes of diversification to navigate an economy in transition from disinflation to reflation and from easy monetary policy to higher costs o ...  Show more

Why investing in non-investment grade bonds, leveraged loans, and preferred stocks is potentially more compelling than investing in common stocks at present.

Topics covered include:

As we get into the new year, we discuss how we’re setting up our portfolios and what we’re investing in for the year ahead. In this episode we:Discuss our financial goals for the year aheadUnpack the concept of Core and Satellite portfolioShare the ETFs we’re buying Show how we’r ...  Show more